PRISM

About this trial

The purpose of this study is to use an assay (TruSight Oncology Comprehensive (TSOComprehensive) assay) to determine gene mutations in people with newly diagnosed breast cancer, as well as people with recurrent and stage IV brain metastatic breast cancer. The TruSight
Oncology Comprehensive assay is a next-generation sequencing (NGS) test used to analyse cancer-related genomic changes in patients, offering a comprehensive view of potential mutations and other alterations that can impact treatment decisions. It analyses 523 cancer-relevant genes from both DNA and RNA to identify variations. It will also look for changes and mutations which may affect cell growth and stability. By identifying relevant mutations and biomarkers, the assay can help oncologists select the most appropriate treatment strategies with the aim of improving patient outcomes.

Patient Profile

People with primary or metastatic breast cancer who have brain metastases, will take part in the study in Ireland.
People with primary breast cancer will be on study for 5 years and those with brain involvement will be studied for 2 years.
In rare cases breast cancer can spread to the brain. If a person develops brain disease while they are in the study they will be followed for another 2 years from time of diagnosis.

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, and University Hospital Galway

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	PRISM
Number:	25-15
Full Title:	Precision Oncology Research Initiative for Metastatic Breast Cancer

Principal Investigator:	Prof Leonie Young (RCSI), Prof Patrick Morris (Beaumont Hospital), Prof Roisin Connolly (CUH), Prof Michael Kerin (University Hospital Galway)
Type:
Sponsor:
Recruitment Started:	Global: Ireland:

Global Recruitment Target:
Ireland Recruitment Target:	1600